• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    New insider Frost Mark T claimed ownership of 25,000 shares (SEC Form 3)

    5/14/25 3:49:59 PM ET
    $HBIO
    Biotechnology: Laboratory Analytical Instruments
    Industrials
    Get the next $HBIO alert in real time by email
    SEC FORM 3 SEC Form 3
    FORM 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0104
    Estimated average burden
    hours per response: 0.5
    1. Name and Address of Reporting Person*
    Frost Mark T

    (Last) (First) (Middle)
    C/O HARVARD BIOSCIENCE, INC.
    84 OCTOBER HILL ROAD

    (Street)
    HOLLISTON MA 01746

    (City) (State) (Zip)
    2. Date of Event Requiring Statement (Month/Day/Year)
    05/12/2025
    3. Issuer Name and Ticker or Trading Symbol
    HARVARD BIOSCIENCE INC [ HBIO ]
    4. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    Director 10% Owner
    X Officer (give title below) Other (specify below)
    Interim CFO
    5. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Beneficially Owned
    1. Title of Security (Instr. 4) 2. Amount of Securities Beneficially Owned (Instr. 4) 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 4. Nature of Indirect Beneficial Ownership (Instr. 5)
    Common Stock 25,000 D
    Table II - Derivative Securities Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 4) 2. Date Exercisable and Expiration Date (Month/Day/Year) 3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) 4. Conversion or Exercise Price of Derivative Security 5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 6. Nature of Indirect Beneficial Ownership (Instr. 5)
    Date Exercisable Expiration Date Title Amount or Number of Shares
    Explanation of Responses:
    Remarks:
    Exhibit 24 - Power of Attorney
    /s/ John Fry, by power of attorney 05/14/2025
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $HBIO alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $HBIO

    DatePrice TargetRatingAnalyst
    4/9/2025Overweight → Sector Weight
    KeyBanc Capital Markets
    3/10/2023$3.00 → $4.00Speculative Buy → Buy
    The Benchmark Company
    More analyst ratings

    $HBIO
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Harvard Bioscience Appoints John Duke to Board of Directors

      HOLLISTON, Mass., June 02, 2025 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (NASDAQ:HBIO) (the "Company") today announced the appointment of John Duke to its board of directors, effective June 2, 2025. Mr. Duke will also serve on the audit and nominating and governance committees. The Company also announced that Katherine Eade has been named Lead Independent Director of the Company's board of directors. "We are pleased to welcome John to Harvard Bioscience's board," said Katherine Eade, Lead Independent Director. "John brings deep experience in life science tools and business execution and has a track record of driving growth and operational excellence." Jim Green, President and CEO, sa

      6/2/25 4:57:22 PM ET
      $HBIO
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Harvard Bioscience Announces First Quarter 2025 Financial Results

      HOLLISTON, Mass., May 12, 2025 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (NASDAQ:HBIO) (the "Company") today announced financial results for the first quarter ended March 31, 2025. Jim Green, Chairman and CEO, said, "First quarter revenues were in line with our expectations, reflecting typical Q4 to Q1 seasonality as well as uncertainty surrounding NIH funding and the evolving tariff situation, especially in relation to sales to China." We are excited by the emerging adoption of our breakthrough MeshMEA™ organoid systems by academic and biopharma customers and encouraged by the market reception of our new SoHo™ telemetry systems. In addition, we remain focused on managing costs and ex

      5/12/25 7:00:00 AM ET
      $HBIO
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Harvard Bioscience Schedules First Quarter 2025 Earnings Conference Call for May 12, 2025 at 8:00 AM ET

      HOLLISTON, Mass., May 05, 2025 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (NASDAQ:HBIO) will announce its financial results for the quarter ended March 31, 2025, before the market opens on May 12, 2025, and will hold a conference call to discuss the results at 8:00 a.m. Eastern Time.  Participants who would like to join the call and ask a question must register here. Once registered, you will receive the dial-in numbers and a unique PIN number.  Participants who would like to join the audio-only webcast should go to our events and presentations on the investor website here. Financial information presented on the call, including the earnings release and a related slide presentation, wi

      5/5/25 4:45:00 PM ET
      $HBIO
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $HBIO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Harvard Bioscience Inc.

      SC 13G/A - HARVARD BIOSCIENCE INC (0001123494) (Subject)

      11/14/24 12:31:23 PM ET
      $HBIO
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • SEC Form SC 13G filed by Harvard Bioscience Inc.

      SC 13G - HARVARD BIOSCIENCE INC (0001123494) (Subject)

      3/19/24 1:02:15 PM ET
      $HBIO
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • SEC Form SC 13G/A filed by Harvard Bioscience Inc. (Amendment)

      SC 13G/A - HARVARD BIOSCIENCE INC (0001123494) (Subject)

      2/14/24 4:05:25 PM ET
      $HBIO
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $HBIO
    Leadership Updates

    Live Leadership Updates

    See more
    • Harvard Bioscience Appoints John Duke to Board of Directors

      HOLLISTON, Mass., June 02, 2025 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (NASDAQ:HBIO) (the "Company") today announced the appointment of John Duke to its board of directors, effective June 2, 2025. Mr. Duke will also serve on the audit and nominating and governance committees. The Company also announced that Katherine Eade has been named Lead Independent Director of the Company's board of directors. "We are pleased to welcome John to Harvard Bioscience's board," said Katherine Eade, Lead Independent Director. "John brings deep experience in life science tools and business execution and has a track record of driving growth and operational excellence." Jim Green, President and CEO, sa

      6/2/25 4:57:22 PM ET
      $HBIO
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Harvard Bioscience Appoints Jennifer Cote as Chief Financial Officer

      HOLLISTON, Mass., June 20, 2023 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (NASDAQ:HBIO) (the "Company") today announced the appointment of Jennifer Cote as the Company's Chief Financial Officer and Treasurer, effective June 19, 2023. Cote joined the Company as Vice President of Global Finance in May 2022 and has served as Interim Chief Financial Officer and Treasurer since January 2023. Jim Green, Chairman and CEO said, "Originally joining us as our Vice President of Global Finance, Jennifer brought extensive experience in areas including global financial and operational leadership, corporate strategy, accounting and internal controls, and strong fiscal management. Since assuming the

      6/20/23 8:01:00 AM ET
      $HBIO
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $HBIO
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Executive Officer Green James W bought $29,100 worth of shares (10,000 units at $2.91), increasing direct ownership by 0.32% to 3,111,091 units (SEC Form 4)

      4 - HARVARD BIOSCIENCE INC (0001123494) (Issuer)

      6/14/24 4:02:29 PM ET
      $HBIO
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Green James W bought $61,400 worth of shares (20,000 units at $3.07), increasing direct ownership by 0.65% to 3,101,091 units (SEC Form 4)

      4 - HARVARD BIOSCIENCE INC (0001123494) (Issuer)

      6/7/24 4:02:24 PM ET
      $HBIO
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $HBIO
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Harvard Biosci downgraded by KeyBanc Capital Markets

      KeyBanc Capital Markets downgraded Harvard Biosci from Overweight to Sector Weight

      4/9/25 8:35:36 AM ET
      $HBIO
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Harvard Biosci upgraded by The Benchmark Company with a new price target

      The Benchmark Company upgraded Harvard Biosci from Speculative Buy to Buy and set a new price target of $4.00 from $3.00 previously

      3/10/23 8:11:48 AM ET
      $HBIO
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • KeyCorp reiterated coverage on Harvard Bioscience with a new price target

      KeyCorp reiterated coverage of Harvard Bioscience with a rating of and set a new price target of $9.00 from $6.00 previously

      3/10/21 5:04:31 PM ET
      $HBIO
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $HBIO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Interim CFO Frost Mark T was granted 100,000 shares, increasing direct ownership by 400% to 125,000 units (SEC Form 4)

      4 - HARVARD BIOSCIENCE INC (0001123494) (Issuer)

      5/14/25 3:52:18 PM ET
      $HBIO
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • New insider Frost Mark T claimed ownership of 25,000 shares (SEC Form 3)

      3 - HARVARD BIOSCIENCE INC (0001123494) (Issuer)

      5/14/25 3:49:59 PM ET
      $HBIO
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Chief Financial Officer Cote Jennifer covered exercise/tax liability with 5,687 shares, decreasing direct ownership by 3% to 159,019 units (SEC Form 4)

      4 - HARVARD BIOSCIENCE INC (0001123494) (Issuer)

      3/21/25 4:50:40 PM ET
      $HBIO
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $HBIO
    SEC Filings

    See more
    • Harvard Bioscience Inc. filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits

      8-K - HARVARD BIOSCIENCE INC (0001123494) (Filer)

      6/2/25 5:00:21 PM ET
      $HBIO
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Amendment: SEC Form SCHEDULE 13G/A filed by Harvard Bioscience Inc.

      SCHEDULE 13G/A - HARVARD BIOSCIENCE INC (0001123494) (Subject)

      5/30/25 11:50:41 AM ET
      $HBIO
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • SEC Form SD filed by Harvard Bioscience Inc.

      SD - HARVARD BIOSCIENCE INC (0001123494) (Filer)

      5/27/25 4:36:27 PM ET
      $HBIO
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $HBIO
    Financials

    Live finance-specific insights

    See more
    • Harvard Bioscience Announces First Quarter 2025 Financial Results

      HOLLISTON, Mass., May 12, 2025 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (NASDAQ:HBIO) (the "Company") today announced financial results for the first quarter ended March 31, 2025. Jim Green, Chairman and CEO, said, "First quarter revenues were in line with our expectations, reflecting typical Q4 to Q1 seasonality as well as uncertainty surrounding NIH funding and the evolving tariff situation, especially in relation to sales to China." We are excited by the emerging adoption of our breakthrough MeshMEA™ organoid systems by academic and biopharma customers and encouraged by the market reception of our new SoHo™ telemetry systems. In addition, we remain focused on managing costs and ex

      5/12/25 7:00:00 AM ET
      $HBIO
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Harvard Bioscience Schedules First Quarter 2025 Earnings Conference Call for May 12, 2025 at 8:00 AM ET

      HOLLISTON, Mass., May 05, 2025 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (NASDAQ:HBIO) will announce its financial results for the quarter ended March 31, 2025, before the market opens on May 12, 2025, and will hold a conference call to discuss the results at 8:00 a.m. Eastern Time.  Participants who would like to join the call and ask a question must register here. Once registered, you will receive the dial-in numbers and a unique PIN number.  Participants who would like to join the audio-only webcast should go to our events and presentations on the investor website here. Financial information presented on the call, including the earnings release and a related slide presentation, wi

      5/5/25 4:45:00 PM ET
      $HBIO
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Harvard Bioscience Announces Fourth Quarter and Full-Year 2024 Financial Results

      HOLLISTON, Mass., March 12, 2025 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (NASDAQ:HBIO) (the "Company") today announced financial results for the fourth quarter and full year ended December 31, 2024. Jim Green, Chairman and CEO, said, "Our fourth quarter saw sequential strengthening in pre-clinical revenues across all regions, while our cellular and molecular technology (CMT) revenues were down slightly from the third quarter, primarily due to reduced purchasing by US academic customers. As expected, our fourth quarter revenues were down compared to the fourth quarter of last year as we navigated a challenging market environment. Green continued, "We are encouraged by the strong mark

      3/12/25 7:21:36 AM ET
      $HBIO
      Biotechnology: Laboratory Analytical Instruments
      Industrials